Summary and Analysis of Aspira Women’s Health Inc. Financial Report

Overview

Aspira Women’s Health Inc. is a company dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. The company plans to broaden its focus to the differential diagnosis of other gynecologic diseases and continue commercializing its existing and new technology through its decentralized technology transfer service platform, Aspira Synergy.

Financial Performance

• Product revenue was $2,404,000 for the three months ended June 30, 2025, a 1% decrease from the same period in 2024. This was due to a decrease in OvaSuite test volume, partially offset by an increase in average unit price (AUP).
• For the six months ended June 30, 2025, product revenue was $4,683,000, a 2% increase from the same period in 2024. The increase was due to the higher AUP, offset by a decrease in OvaSuite test volume.
• Gross profit margin for product revenue increased to 63.8% for the three months ended June 30, 2025, compared to 58.6% for the same period in 2024. For the six months ended June 30, 2025, gross profit margin increased to 66.1%, compared to 57.6% in the prior year.
• Operating expenses decreased significantly, with research and development down 26% and 10%, sales and marketing down 68% and 56%, and general and administrative down 28% and 20% for the three and six month periods, respectively.
• The company reported net losses of $2,666,000 and $4,519,000 for the three and six month periods ended June 30, 2025, respectively, an improvement from the prior year.

Strengths and Weaknesses

Strengths:

• Increased gross profit margins due to cost-cutting measures
• Significant reductions in operating expenses across R&D, sales/marketing, and G&A
• Successful development and commercialization of new products like OvaWatch

Weaknesses:

• Declining test volumes, partially offsetting revenue growth from higher AUP
• Continued net losses and negative cash flows from operations
• Delisting from Nasdaq and trading on the OTC markets
• Termination of ARPA-H contract for the ENDOinform program

Outlook

• The company expects revenue to increase in the third quarter of 2025 due to a focus on revenue-generating payers.
• Research and development expenses are expected to increase modestly, while sales/marketing and G&A expenses are expected to decrease.
• Significant uncertainty remains around the company’s ability to continue as a going concern, with working capital levels potentially insufficient to fund operations over the next 12 months.
• The company plans to raise additional capital through various means, including public/private equity, debt financing, collaborations, and government funding, but there is no assurance of success.
• Successful commercialization of new products like OvaWatch and securing payer coverage will be critical to the company’s future.

Overall, Aspira Women’s Health faces significant financial challenges but has taken steps to improve its operational efficiency. The company’s ability to secure additional funding and drive adoption of its newer products will be key to its long-term viability.